Aquinox Pharmaceuticals Company Profile (NASDAQ:AQXP)

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals logoAquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company's product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AQXP
  • CUSIP:
Key Metrics:
  • Previous Close: $13.62
  • 50 Day Moving Average: $11.78
  • 200 Day Moving Average: $8.98
  • 52-Week Range: $6.01 - $16.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.19
  • P/E Growth: 0.00
  • Market Cap: $229.95M
  • Outstanding Shares: 17,212,000
  • Beta: -18.91
Profitability:
  • Return on Equity: -27.16%
  • Return on Assets: -25.72%
Debt:
  • Current Ratio: 7.97%
  • Quick Ratio: 7.97%
Additional Links:
Companies Related to Aquinox Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Aquinox Pharmaceuticals (NASDAQ:AQXP) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $20.33 (52.20% upside)

Analysts' Ratings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Show:
DateFirmActionRatingPrice TargetDetails
8/17/2016Canaccord GenuityReiterated RatingBuy$22.00View Rating Details
8/5/2016Jefferies GroupBoost Price TargetHold$7.00 -> $9.00View Rating Details
5/12/2016Needham & Company LLCInitiated CoverageBuy$25.00View Rating Details
3/16/2016Leerink SwannLower Price TargetOutperform$26.00 -> $21.00View Rating Details
11/3/2015Cowen and CompanyReiterated RatingBuy$23.00View Rating Details
10/6/2015GuggenheimInitiated CoverageBuy$22.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016        
8/4/2016Q2($0.41)($0.63)ViewN/AView Earnings Details
5/10/2016Q1($0.35)($0.39)ViewN/AView Earnings Details
3/14/2016Q4($0.37)($0.26)ViewN/AView Earnings Details
11/10/2015Q315($0.45)($0.43)ViewN/AView Earnings Details
8/6/2015Q215($0.56)($0.44)ViewN/AView Earnings Details
5/12/2015Q115($0.83)($0.60)ViewN/AView Earnings Details
4/15/2015($0.57)($0.78)ViewN/AView Earnings Details
3/16/2015($0.76)($0.78)ViewN/AView Earnings Details
11/4/2014($0.29)($0.59)ViewN/AView Earnings Details
8/11/2014($0.27)($0.51)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Current Year EPS Consensus Estimate: $-2.31 EPS
Next Year EPS Consensus Estimate: $-2.16 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.38)($0.31)($0.35)
Q2 20162($0.47)($0.42)($0.45)
Q3 20162($0.53)($0.45)($0.49)
Q4 20162($0.59)($0.49)($0.54)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 89.41%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/20/2016Bros. Advisors Lp BakerMajor ShareholderBuy2,783,605$12.25$34,099,161.25View SEC Filing  
3/16/2016Bros. Advisors Lp BakerMajor ShareholderBuy471,667$7.99$3,768,619.33View SEC Filing  
3/15/2016Bros. Advisors Lp BakerMajor ShareholderBuy109,912$7.98$877,097.76View SEC Filing  
1/26/2016Bros. Advisors Lp BakerMajor ShareholderBuy140,786$10.80$1,520,488.80View SEC Filing  
1/20/2016Bros. Advisors Lp BakerMajor ShareholderBuy112,034$9.48$1,062,082.32View SEC Filing  
1/19/2016Bros. Advisors Lp BakerMajor ShareholderBuy78,045$9.11$710,989.95View SEC Filing  
1/15/2016Bros. Advisors Lp BakerMajor ShareholderBuy202,623$8.28$1,677,718.44View SEC Filing  
9/10/2015Bros. Advisors Lp BakerMajor ShareholderBuy2,480,032$15.50$38,440,496.00View SEC Filing  
8/24/2015David Chilton MitchellVPBuy3,575$17.81$63,670.75View SEC Filing  
8/12/2015Kamran AlamCFOSell29,079$18.67$542,904.93View SEC Filing  
8/12/2015Lloyd MackenzieVPSell35,887$18.67$670,010.29View SEC Filing  
12/17/2014& Johnson JohnsonMajor ShareholderSell8,100$7.62$61,722.00View SEC Filing  
12/12/2014& Johnson JohnsonMajor ShareholderSell5,000$7.51$37,550.00View SEC Filing  
12/10/2014& Johnson JohnsonMajor ShareholderSell8,300$7.72$64,076.00View SEC Filing  
12/9/2014& Johnson JohnsonMajor ShareholderSell5,000$7.73$38,650.00View SEC Filing  
12/8/2014& Johnson JohnsonMajor ShareholderSell2,000$7.69$15,380.00View SEC Filing  
12/5/2014& Johnson JohnsonMajor ShareholderSell15,900$7.76$123,384.00View SEC Filing  
12/1/2014& Johnson JohnsonMajor ShareholderSell1,200$7.54$9,048.00View SEC Filing  
11/26/2014& Johnson JohnsonMajor ShareholderSell2,000$7.75$15,500.00View SEC Filing  
11/24/2014& Johnson JohnsonMajor ShareholderSell9,500$8.14$77,330.00View SEC Filing  
3/12/2014Pfizer IncMajor ShareholderBuy272,727$11.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aquinox Pharmaceuticals (NASDAQ:AQXP)
DateHeadline
News IconWhat are Brokerage Firms Saying About Aquinox Pharmaceuticals ... - Frisco Fastball (NASDAQ:AQXP)
friscofastball.com - September 30 at 8:47 AM
News IconNew Analyst Ratings On Aquinox Pharmaceuticals, Inc. (AQXP ... - NewsDen (NASDAQ:AQXP)
newsden.net - September 29 at 8:21 AM
News IconLatest Analyst Ratings For Aquinox Pharmaceuticals, Inc. (AQXP) - The De Soto Edge (NASDAQ:AQXP)
desotoedge.com - September 29 at 8:21 AM
News IconAquinox Pharmaceuticals Inc (NASDAQ:AQXP) Looks Strong Ahead Of Phase III Completion - Street Register (NASDAQ:AQXP)
streetregister.com - September 28 at 8:21 AM
News IconAquinox Pharmaceuticals Inc (NASDAQ:AQXP) Looks Strong Ahead Of Phase III Completion (NASDAQ:AQXP)
streetregister.com - September 27 at 8:00 AM
barrons.com logo[$$] Two Cancer Biotechs See Bullish Insider Buying (NASDAQ:AQXP)
www.barrons.com - September 27 at 8:00 AM
nasdaq.com logoAquinox Announces Closing of $75.4 Million Public Offering of Common (NASDAQ:AQXP)
www.nasdaq.com - September 24 at 8:52 AM
nasdaq.com logoAquinox Announces Closing of $75.4 Million Public Offering of Common Stock, Including Full Exercise (NASDAQ:AQXP)
m.nasdaq.com - September 24 at 8:52 AM
nasdaq.com logoAquinox Announces Closing of $75.4 Million Public Offering of Common Stock, Including Full Exercise of Underwriters ... - Nasdaq (NASDAQ:AQXP)
www.nasdaq.com - September 23 at 3:58 PM
finance.yahoo.com logoAquinox Announces Closing of $75.4 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares (NASDAQ:AQXP)
finance.yahoo.com - September 23 at 3:58 PM
News IconAquinox Pharmaceuticals Announces $65 Million Public Offering of Common Stock (NASDAQ:AQXP)
www.bctechnology.com - September 22 at 3:31 PM
insidermonkey.com logoAquinox Pharmaceuticals Inc (AQXP): Baker Bros. Advisors Pushes Stake to Over 45% (NASDAQ:AQXP)
www.insidermonkey.com - September 22 at 3:31 PM
4-traders.com logoAquinox Pharmaceuticals : Prices Public Offering of Common Stock (NASDAQ:AQXP)
www.4-traders.com - September 22 at 9:26 AM
News IconAquinox Pharmaceuticals Coverage Initiated at Guggenheim (AQXP) - Petro Global News 24 (NASDAQ:AQXP)
petroglobalnews24.com - September 21 at 4:28 PM
biz.yahoo.com logoAQUINOX PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial (NASDAQ:AQXP)
biz.yahoo.com - September 21 at 8:41 AM
News Icon[Stock]'s Company Shares [IncreasedDecreased] [IncreaseDecrease] After [HighLow] Volatility - Post News (NASDAQ:AQXP)
www.kentuckypostnews.com - September 20 at 3:34 PM
streetinsider.com logoAquinox Pharma (AQXP) Plans Common Stock Offering (NASDAQ:AQXP)
www.streetinsider.com - September 20 at 9:30 AM
marketwatch.com logoAquinox Prices Public Offering of Common Stock (NASDAQ:AQXP)
www.marketwatch.com - September 20 at 9:30 AM
4-traders.com logoAquinox Pharmaceuticals : Announces Proposed Public Offering of Common Stock (NASDAQ:AQXP)
www.4-traders.com - September 20 at 9:30 AM
streetinsider.com logoAquinox Pharma (AQXP) Plans Common Stock Offering - StreetInsider.com (NASDAQ:AQXP)
www.streetinsider.com - September 19 at 4:30 PM
finance.yahoo.com logoAquinox Pharmaceuticals Announces Proposed Public Offering of Common Stock (NASDAQ:AQXP)
finance.yahoo.com - September 19 at 4:30 PM
finance.yahoo.com logoAquinox Pharmaceuticals (AQXP) is in Overbought Territory: What's Next? (NASDAQ:AQXP)
finance.yahoo.com - September 16 at 12:14 PM
News IconInvestor Scope: Checking in on Shares of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) - Post News (NASDAQ:AQXP)
www.kentuckypostnews.com - September 14 at 8:04 AM
News IconMarket Focus: Checking on Session Activity for Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Shares - Post News (NASDAQ:AQXP)
www.kentuckypostnews.com - September 12 at 3:33 PM
News IconAnalysts Place Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Under the Lens of the Microscope - Post News (NASDAQ:AQXP)
www.kentuckypostnews.com - September 12 at 8:21 AM
News IconRa Capital Management buys $15752306 stake in Aquinox Pharmaceuticals Inc (AQXP) - National Daily Press (NASDAQ:AQXP)
www.nationaldailypress.com - September 12 at 8:21 AM
News IconMarket Review: Watching Session Activity of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Shares - Post News (NASDAQ:AQXP)
www.kentuckypostnews.com - September 9 at 3:31 PM
News IconStock Perspective: Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Earnings in View - Frisco Fastball (NASDAQ:AQXP)
friscofastball.com - September 8 at 10:43 AM
News IconTrading Update: Following Activity of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Shares During the Current Session - Post News (NASDAQ:AQXP)
www.kentuckypostnews.com - September 7 at 3:32 PM
News IconStock Showing Gains in Today's Session: Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) - Post News (NASDAQ:AQXP)
www.kentuckypostnews.com - September 7 at 3:32 PM
streetinsider.com logoAquinox Pharma (AQXP) Commences Dosing in AQX-1125 PHase 3 as IC/BPS Treatment - StreetInsider.com (NASDAQ:AQXP)
www.streetinsider.com - September 6 at 3:31 PM
News IconInvestor Beat: Watching Activity of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Shares During the Session - Post News (NASDAQ:AQXP)
www.kentuckypostnews.com - September 3 at 8:23 AM
News IconExpert Analysts Position for: Gold Fields Limited (NYSE:GFI) , Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) - Wall Street Times (press release) (NASDAQ:AQXP)
www.wallstreetnews24.com - September 2 at 8:13 AM
News IconStock Ticking Higher in Trading: Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) - Post News (NASDAQ:AQXP)
www.kentuckypostnews.com - September 1 at 3:33 PM
News IconMarket Checkup: Performance Review on Shares of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) - Post News (NASDAQ:AQXP)
www.kentuckypostnews.com - August 31 at 3:33 PM
News IconHow is the Crowd Rating Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Shares? - Post News (NASDAQ:AQXP)
www.kentuckypostnews.com - August 30 at 10:55 AM
News IconAnalyst Rating Update on Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) - Post News (NASDAQ:AQXP)
www.kentuckypostnews.com - August 23 at 3:35 PM
News IconStock Analyst Estimates on Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) - Post News (NASDAQ:AQXP)
www.kentuckypostnews.com - August 19 at 11:57 AM
finance.yahoo.com logoEdited Transcript of AQXP earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:AQXP)
finance.yahoo.com - August 12 at 9:00 PM
finance.yahoo.com logoAQUINOX PHARMACEUTICALS, INC Financials (NASDAQ:AQXP)
finance.yahoo.com - August 12 at 3:43 PM
fxpips.com logoStock Gaps Down Summary – QVCB, AQXP, FLDM, FTD, CPSI, SWIR, HDP, FEYE (NASDAQ:AQXP)
www.fxpips.com - August 8 at 8:21 AM
globenewswire.com logoAquinox Pharmaceuticals Announces Second Quarter 2016 Financial Results - GlobeNewswire (press release) (NASDAQ:AQXP)
globenewswire.com - August 5 at 11:58 AM
sg.finance.yahoo.com logoAquinox reports 2Q loss (NASDAQ:AQXP)
sg.finance.yahoo.com - August 5 at 11:58 AM
finance.yahoo.com logo5:25 pm Aquinox Pharma reports Q2; on track to initiate enrollment in Phase 3 clinical trial with AQX-1125 in interstitial cystitis/bladder pain syndrome (IC/BPS) this quarter (NASDAQ:AQXP)
finance.yahoo.com - August 4 at 9:18 PM
biz.yahoo.com logoQ2 2016 Aquinox Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:AQXP)
biz.yahoo.com - August 4 at 12:04 PM
News IconAquinox to Present at Canaccord Genuity 36th Annual Growth Conference (NASDAQ:AQXP)
www.pharmiweb.com - August 2 at 3:34 PM
News IconAquinox Pharmaceuticals to Announce Second Quarter 2016 Financial Results - PharmiWeb.com (press release) (NASDAQ:AQXP)
www.pharmiweb.com - August 2 at 8:22 AM
publicnow.com logoAquinox Pharmaceuticals to Announce Second Quarter 2016 Financial Results (NASDAQ:AQXP)
www.publicnow.com - August 1 at 3:33 PM
News IconAquinox Pharmaceuticals, Inc. (NASDAQ:AQXP): A Quick Review & Update - Press Telegraph (NASDAQ:AQXP)
presstelegraph.com - July 23 at 3:31 PM
News IconEquity Roundup: Stock Performance Focus on Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) - Press Telegraph (NASDAQ:AQXP)
presstelegraph.com - July 23 at 6:48 AM

Social

Aquinox Pharmaceuticals (NASDAQ:AQXP) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff